Literature DB >> 15664799

Acetazolamide-enhanced neuroSPECT scan reveals functional impairment after minimal traumatic brain injury not otherwise discernible.

Gavriel Barkai1, Elinor Goshen, S Tzila Zwas, Ornah T Dolberg, Chaim G Pick, Omer Bonne, Shaul Schreiber.   

Abstract

A patient suffering from aggressive personality changes and cognitive impairment following head trauma, without neurological or anatomical imaging findings, underwent neuroSPECT scans with and without acetazolamide injection, both before treatment and during treatment with valproate. Acetazolamide injection induced increased prefrontal perfusion not evident at baseline. Valproate treatment was associated with increased prefrontal perfusion concomitant with clinical improvement and abolished response to acetazolamide challenge.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15664799     DOI: 10.1016/j.pscychresns.2004.09.004

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

Review 1.  Cerebral Microvascular Injury: A Potentially Treatable Endophenotype of Traumatic Brain Injury-Induced Neurodegeneration.

Authors:  Danielle K Sandsmark; Asma Bashir; Cheryl L Wellington; Ramon Diaz-Arrastia
Journal:  Neuron       Date:  2019-08-07       Impact factor: 17.173

2.  Cerebral perfusion disturbances in chronic mild traumatic brain injury correlate with psychoemotional outcomes.

Authors:  Efrosini Papadaki; Eleftherios Kavroulakis; Katina Manolitsi; Dimitrios Makrakis; Emmanouil Papastefanakis; Pelagia Tsagaraki; Styliani Papadopoulou; Alexandros Zampetakis; Margarita Malliou; Antonios Vakis; Panagiotis Simos
Journal:  Brain Imaging Behav       Date:  2021-06       Impact factor: 3.978

3.  Assessment of cerebrovascular dysfunction after traumatic brain injury with fMRI and fNIRS.

Authors:  Franck Amyot; Kimbra Kenney; Emily Spessert; Carol Moore; Margalit Haber; Erika Silverman; Amir Gandjbakhche; Ramon Diaz-Arrastia
Journal:  Neuroimage Clin       Date:  2019-11-11       Impact factor: 4.881

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.